ixoberogene soroparvovec
AXP000258.1 · Viral vector gene therapy
- Platform
- AAV.7m8 vector
- Originator
- Adverum Biotechnologies
- Sponsor
- Adverum Biotechnologies
Names
| Name | Type | Source |
|---|---|---|
| ixoberogene soroparvovec | preferred name | curator |
| ixo-vec | synonym | ctgov |
| ADVM-022 | former code | ctgov |
Virus
- Role
- In vivo gene transfer
- Family
- Parvoviridae
- Virus
- adeno-associated virus (7m8 capsid variant)
- Strain
- AAV.7m8
- Replication
- non replicating
- Modifications
- 7m8 peptide-insertion capsid variant
- Transgenes
- aflibercept
- Route
- intravitreal
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (8)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07630649 | Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration | Recruiting | Phase 2 | 2026-06-02 | 2031-06 | 15 | Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD |
| NCT07482176 | Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) | Recruiting | Phase 3 | 2026-03-16 | 2027-11-15 | 534 | Neovascular Age-Related Macular Degeneration (nAMD); Wet AMD |
| NCT06856577 | Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration | Active not recruiting | Phase 3 | 2025-02-28 | 2026-12-22 | 311 | Neovascular Age-Related Macular Degeneration (nAMD); Wet AMD |
| NCT05536973 | Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA] | Active not recruiting | Phase 2 | 2022-08-23 | 2024-08-26 | 69 | Neovascular Age-related Macular Degeneration |
| NCT05607810 | Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT) | Active not recruiting | 2022-08-10 | 2031-04 | 22 | Diabetic Macular Edema; Diabetic Retinopathy | |
| NCT04645212 | Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT] | Active not recruiting | 2020-12-14 | 2030-06-26 | 23 | Neovascular Age-related Macular Degeneration; Wet Age-related Macular Degeneration | |
| NCT04418427 | ADVM-022 Intravitreal Gene Therapy for DME | Completed | Phase 2 | 2020-05-28 | 2022-11-22 | 36 | Diabetic Macular Edema; Diabetic Retinopathy |
| NCT03748784 | ADVM-022 Intravitreal Gene Therapy for Wet AMD | Completed | Phase 1 | 2018-11-14 | 2022-06-22 | 30 | Neovascular Age-related Macular Degeneration; Wet Age-related Macular Degeneration |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 38152412 | Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study. | EClinicalMedicine | 2024 | cited by trial NCT03748784 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41490387 | Emerging solutions for neovascular age-related macular degeneration. | Current opinion in ophthalmology | 2026 | name in abstract: ADVM-022 |
| PMID 41688763 | AAV-based gene therapies for neovascular AMD. | Gene therapy | 2026 | name in abstract: ADVM-022 |
| PMID 39379521 | Exploring new horizons in neovascular age-related macular degeneration: novel mechanisms of action and future therapeutic avenues. | Eye (London, England) | 2025 | name in abstract: ixo-vec |
| PMID 40092639 | Nonclinical study of ixo-vec gene therapy for nAMD supports efficacy for a human dose of 6E10 vg/eye and staggered dosing of fellow eyes. | Molecular therapy. Methods & clinical development | 2025 | name in title: ixo-vec |
| PMID 40293479 | Gene therapy in neovascular age related macular degeneration: an update. | Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie | 2025 | name in abstract: ixoberogene soroparvovec |
| PMID 40364236 | Gene Therapy in Diabetic Retinopathy and Diabetic Macular Edema: An Update. | Journal of clinical medicine | 2025 | name in abstract: ADVM-022 |
| PMID 40601510 | Gene Therapy in Age-related Macular Degeneration. | International ophthalmology clinics | 2025 | name in abstract: ADVM-022 |
| PMID 40689796 | A Semimechanistic Ocular Pharmacokinetic Model for ADVM-022 Gene Therapy Describing the Dose-Exposure Relationship in Monkeys and the Scaling to Human. | Molecular pharmaceutics | 2025 | name in title: ADVM-022 |
| PMID 38397064 | A New Generation of Gene Therapies as the Future of Wet AMD Treatment. | International journal of molecular sciences | 2024 | name in abstract: ADVM-022 |
| PMID 38927656 | Gene Therapy for Non-Hereditary Retinal Disease: Age-Related Macular Degeneration, Diabetic Retinopathy, and Beyond. | Genes | 2024 | name in abstract: ixoberogene soroparvovec |
| PMID 35017696 | Review of gene therapies for age-related macular degeneration. | Eye (London, England) | 2022 | name in abstract: ADVM-022 |
| PMID 33532145 | Long-Term Safety Evaluation of Continuous Intraocular Delivery of Aflibercept by the Intravitreal Gene Therapy Candidate ADVM-022 in Nonhuman Primates. | Translational vision science & technology | 2021 | name in title: ADVM-022 |
| PMID 33835848 | Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema. | Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics | 2021 | name in title: ADVM-022 |
| PMID 34188445 | Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration. | Drug design, development and therapy | 2021 | name in abstract: ADVM-022 |
| PMID 32671137 | Analysis of Aflibercept Expression in NHPs following Intravitreal Administration of ADVM-022, a Potential Gene Therapy for nAMD. | Molecular therapy. Methods & clinical development | 2020 | name in title: ADVM-022 |
| PMID 30528929 | Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration. | Molecular therapy : the journal of the American Society of Gene Therapy | 2019 | name in title: ADVM-022 |
| PMID 31298960 | Innovative therapies for neovascular age-related macular degeneration. | Expert opinion on pharmacotherapy | 2019 | name in abstract: ADVM-022 |
Notes
Intravitreal AAV.7m8 vector expressing aflibercept for neovascular AMD. Phase 1 OPTIC NCT03748784 (published), then the phase 3 ARTEMIS NCT06856577 and AQUARIUS NCT07482176. Formerly ADVM-022. `targets` empty: the transgene is a receptor-Fc fusion protein, not a human gene to be replaced.
How to cite
ixoberogene soroparvovec (AXP000258.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000258.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.